Protalix (PLX) AI Stock Analysis

• Market Cap: $119.41M
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): 35.7
• Beta (1Y): 0.64
• Revenue Growth: 0.18%
• EPS Growth: -55.15%
• Country: US
• Employees: 213
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 79,607,120
• 10 Day Avg. Volume: 1,890,889
• 30 Day Avg. Volume: 1,049,076
• PEG Ratio: 1.11
• Price to Book (P/B): -0.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.44
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 0.47
• Enterprise Value/Gross Profit: 3.07
• Enterprise Value/Ebitda: -19.56
• 1Y Price Target: $15.00
• Price Target Upside: 900.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: $1.50 ▲(0.00%Upside)

The stock's overall score is driven by significant improvements in financial performance and strong guidance from the earnings call. However, technical analysis indicates current bearish trends and valuation concerns, impacting the score negatively.

Positive Factors

Commercial Approval

Elfabrio remains favorable with commercial approval across 23 territories globally for the treatment of Fabry disease.

Debt Management

Protalix is now debt-free, having repaid all its 7.50% senior secured convertible promissory notes last year in full from cash on hand.

Market Opportunity

Protalix's management indicated that the total Fabry disease market opportunity may raise significantly by 2030, with potential substantial royalty streams from Elfabrio.

Negative Factors

Financial Performance

Protalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.

Protalix Business Overview & Revenue Model

Company Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

How the Company Makes Money

Protalix generates revenue through the development and commercialization of its proprietary products and by licensing its technology to other pharmaceutical companies. A significant portion of its income comes from product sales, particularly its FDA-approved treatments. The company also earns revenue through milestone payments and royalties from strategic partnerships and collaborations with other pharmaceutical firms, leveraging its ProCellEx platform to develop new therapeutic proteins. These partnerships help expand its market reach and contribute to its earnings by sharing the costs and potential profits of drug development.

Protalix Financial Statement Overview

Summary

Protalix has shown significant improvement in profitability and cash flow, which are crucial for financial stability. While leverage remains a concern due to a high debt-to-equity ratio, the overall trend suggests positive momentum in financial health. Continued focus on revenue growth and debt reduction will be vital.

Income Statement

The company has demonstrated a positive turnaround in profitability over the last few years. Gross profit margins have been healthy, and there was a notable improvement in net income, moving from losses to profits recently. However, revenue growth has been inconsistent with a decline in the latest period, and EBIT margins are still relatively low, indicating room for operational improvements.

Balance Sheet

Protalix's balance sheet shows a significant reduction in total debt, which is a positive sign for financial health. The equity position has improved from negative to positive, enhancing the equity ratio. However, the debt-to-equity ratio is still high, indicating potential leverage risks. The company needs to continue strengthening its equity to mitigate these risks further.

Cash Flow

The company has shown a strong improvement in cash flow, moving from negative free cash flow to positive in the latest period. The operating cash flow to net income ratio indicates a healthy conversion of profits into cash. However, the free cash flow growth rate is volatile, suggesting potential fluctuations in cash generation capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	59.76M	53.40M	65.49M	47.64M	38.35M	62.90M
Gross Profit	29.87M	29.08M	42.51M	28.05M	22.00M	52.02M
EBITDA	7.16M	6.52M	12.94M	-10.78M	-18.94M	4.45M
Net Income	3.91M	2.93M	8.31M	-14.93M	-27.58M	-6.52M
Balance Sheet
Total Assets	73.89M	73.42M	84.43M	55.79M	73.67M	67.93M
Cash, Cash Equivalents and Short-Term Investments	34.74M	34.83M	44.56M	22.18M	38.98M	38.55M
Total Debt	5.24M	5.53M	26.28M	33.47M	33.47M	64.40M
Total Liabilities	28.68M	30.21M	50.87M	66.43M	79.70M	94.97M
Stockholders Equity	45.21M	43.21M	33.57M	-10.64M	-6.04M	-27.04M
Cash Flow
Free Cash Flow	-1.56M	7.39M	-2.47M	-25.63M	-11.74M	-26.76M
Operating Cash Flow	-572.00K	8.67M	-1.32M	-25.00M	-10.29M	-26.11M
Investing Cash Flow	4.51M	4.22M	-16.71M	-5.04M	18.92M	-19.95M
Financing Cash Flow	-11.72M	-16.79M	24.67M	8.24M	12.08M	46.47M

Protalix Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Neutral. The current price of 1.5 is above the 20-day moving average (MA) of 1.49, below the 50-day MA of 1.90, and below the 200-day MA of 1.88, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 44.63 is Neutral, neither overbought nor oversold. The STOCH value of 47.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLX.

Protalix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LXRX	60 Neutral	$332.63M	―	-86.09%	―	1250.63%	37.24%
PLX	56 Neutral	$119.41M	35.71	10.42%	―	0.18%	-55.15%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
DBVT	51 Neutral	$269.40M	―	-198.47%	―	―	-38.74%
TERN	45 Neutral	$372.06M	―	-32.12%	―	―	10.98%
HURA	36 Underperform	$121.49M	―	-244.16%	―	―	77.12%
GOSS	35 Underperform	$284.13M	―	-500.57%	―	―	81.94%

Protalix Corporate Events

Protalix Holds Annual Stockholders Meeting in Tel Aviv

On June 26, 2025, Protalix Biotherapeutics, Inc. held its Annual Meeting of Stockholders in Tel Aviv, Israel. During the meeting, stockholders elected eight board members, approved executive compensation on a non-binding basis, and ratified the appointment of Kesselman & Kesselman as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.

Protalix CFO Eyal Rubin Announces Resignation

On April 21, 2025, Eyal Rubin, the Senior Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., announced his resignation to pursue other opportunities, effective in six months. During his tenure, Rubin significantly contributed to the company’s financial and product development advancements. He will continue in his role during the transition period, receiving full salary and benefits, and will be entitled to severance and accelerated equity vesting upon his departure.